Shen Qi Wan
Related Topics
Published research studies are articles that present the findings of original research that has undergone a peer-review process and has been made publicly available in scholarly journals, books or other media.
Shen Qi Wan ameliorates nephritis in chronic kidney disease via AQP1 and DEFB1 regulation
2024 Jan Biomedicine & Pharmacotherapy Liu Y, Hong X, Liu L, Li X, Huang S, Luo Q, et al.
SQW demonstrated a reduction in renal collagen deposition, decreased serum inflammatory cytokine levels, and improved renal function in adenine-induced CKD mice and AQP1-/- mice. The potential therapeutic target β-defensin 1 (DEFB1) was identified, and SQW was found to alleviate inflammatory responses by fostering AQP1-mediated DEFB1 expression. The renal-protective effect of SQW was partly attenuated after AQP1 gene knockout, highlighting its potential as a novel strategy for CKD management.
Experimental Study Shen Qi Wan
Multiple Mechanisms of Shenqi Pill in Treating Nonalcoholic Fatty Liver Disease Based on Network Pharmacology and Molecular Docking
2022 Jun 26 Evidence-Based Complementary and Alternative Medicine Tong X, Xu S, Zhai D
The study identified 15 anti-NAFLD bioactive ingredients in SQP, including quercetin, kaempferol, stigmasterol, diosgenin, and tetrahydroalstonine. Key target proteins against NAFLD were AKT1, TNF, MAPK8, IL-6, and VEGFA. The main pathways involved PI3K/Akt signaling, HIF-1 signaling, MAPK signaling, and TNF signaling. Molecular docking predicted binding of quercetin, kaempferol, stigmasterol, diosgenin, and tetrahydroalstonine with AKT1, TNF, and MAPK8, suggesting their potential role in SQP's anti-NAFLD effects.
Network Pharmacology Non-Alcoholic Fatty Liver Disease Shen Qi WanSign In
Users not signed in are limited to viewing the 5 most recent items of content.
Share Shen Qi Wan
